Who this is for:
People diagnosed with advanced cancer — including melanoma, lung cancer, kidney cancer, or bile duct cancer — who want to understand why modern immunotherapy has changed survival for some patients, and what that really means.
For many years in oncology, we focused on one number: the median survival.
If the median improved by a few months, we called it progress.
But something fundamental changed in the last decade.
Immunotherapy did not just shift the middle.
In several cancers, it lifted the tail of the survival curve.
And that changes everything.
What does “lifting the tail” mean?
Imagine a survival curve as a line that gradually slopes downward over time.
The median tells you where the middle sits. It tells you when half the patients are alive and half have passed away.
But the tail — the far right end of that curve — tells you something more powerful:
Are a meaningful number of patients alive years later?
In modern oncology, that tail is where transformation lives.
Melanoma: From Months to Long-Term Survival
In advanced melanoma, immunotherapy dramatically changed outcomes. Before checkpoint inhibitors, long-term survival was rare. Less than 5% lived for more than 5 years
With modern immunotherapy combinations, approximately half of patients are alive at five years. Infact 72% was surviving at 6.5 year follow up which is phenomenal achievement. It lifted the tail
Non–Small Cell Lung Cancer
In advanced lung cancer, adding immunotherapy to chemotherapy has led to durable long-term survival in a meaningful minority of patients.
Five-year survival rates have significantly improved compared with historical chemotherapy-alone outcomes.
Not everyone benefits.
But a subgroup clearly does. Without immunotherapy only 11% survived for 5 years and the rate was double with immunotherapy. It lifted the tail
Kidney Cancer
In metastatic kidney cancer, immunotherapy-based combinations have produced durable remissions in patients who historically had limited long-term survival.
Again, the median moves modestly — but the tail extends meaningfully.
In the intent-to-treat population, 18% of the NIVO+IPI-treated and 5% of SUN-treated patients are surviving treatment-free. It lifted the tail.
Advanced Bile Duct Cancer (Cholangiocarcinoma) – TOPAZ-1
We are now seeing the same pattern in advanced biliary tract cancer.
In the international TOPAZ-1 trial, adding immunotherapy (durvalumab) to chemotherapy improved overall survival.
The median increased from 11.3 months to 12.9 months.
But the more important finding appeared later:
At two years, survival was approximately 23.6% with immunotherapy compared to 11.5% with chemotherapy alone.
At three years, survival was 14.6% versus 4.1%.
That is more than a tripling of long-term survival at three years. It lifted the tail
You can read a full breakdown of the TOPAZ-1 study here:
[Internal link: Advanced bile duct cancer: how immunotherapy changed survival (TOPAZ-1)]
This is lifting the tail.
Why This Matters
Immunotherapy is not a miracle drug.
It does not work for every patient.
It does not replace biology.
Tumour biology still sets the stage.
But the right treatment layer — applied early and correctly — can shift long-term outcomes for a meaningful minority of patients.
And in advanced cancer, even shifting the tail matters.
Australia, Access, and Decision-Making
For patients receiving cancer treatment in Australia, immunotherapy is now integrated into first-line treatment for multiple advanced cancers, including melanoma, lung cancer, kidney cancer, and biliary tract cancer.
Access, sequencing, molecular testing, and multidisciplinary input all influence whether these modern strategies are applied appropriately.
For Sri Lankan patients considering treatment in Australia, this distinction can be particularly important.
Access to immunotherapy, clinical trials, and molecular testing may vary significantly between healthcare systems.
Modern oncology is no longer about one uniform pathway. It is about layering treatments strategically and sequencing them thoughtfully.
Biology matters.
But so do decisions.
The Bigger Shift in Oncology
The goal of cancer treatment used to be extending the median by months.
The goal today is identifying the subgroup of patients who can achieve durable survival — and ensuring they are given the opportunity to benefit.
That is the difference between shifting the middle and lifting the tail.
And that is why immunotherapy has changed the outlook in multiple advanced cancers.
Key Takeaway
• Immunotherapy has reshaped long-term survival in several advanced cancers.
• The most important changes are seen in long-term survivors, not just the median.
• Access, timing, and treatment sequencing matter — particularly for patients seeking care in Australia.
Advanced Melanoma (The 6.5-Year Plateau):
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229
Lung Cancer (The 5-Year Milestone):
Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992-1998. doi:10.1200/JCO.22.01989
Kidney Cancer (The 5-Year Milestone):
Mantia CM, Jegede OA, Plimack ER, et al. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. J Immunother Cancer. 2024;12(7):e009495. Published 2024 Jul 25. doi:10.1136/jitc-2024-009495
Bile Duct Cancer (The 3-Year Update):
Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2022;23(9):1119-1131. Updated 3-year data: Oh DY, et al. Journal of Hepatology. 2025;83(Suppl 4).